Zafgen Inc. (NASDAQ:ZFGN) shares saw strong trading volume on Monday . 369,055 shares changed hands during mid-day trading, an increase of 3% from the previous session’s volume of 358,236 shares.The stock last traded at $6.93 and had previously closed at $6.61.

Several analysts have commented on the company. Royal Bank Of Canada reissued an “outperform” rating and issued a $19.00 price objective on shares of Zafgen in a report on Tuesday, April 5th. FBR & Co reissued a “buy” rating and issued a $20.00 price objective on shares of Zafgen in a report on Monday, April 4th. Leerink Swann reissued a “hold” rating and issued a $6.00 price objective on shares of Zafgen in a report on Monday, April 11th. Finally, Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $7.25 price objective on the stock in a report on Thursday, May 12th. Four research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zafgen currently has an average rating of “Buy” and an average target price of $11.94.

The company’s market cap is $188.72 million. The company has a 50-day moving average price of $6.46 and a 200 day moving average price of $6.57.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.09. During the same period in the previous year, the company earned ($0.53) EPS. Analysts forecast that Zafgen Inc. will post ($2.81) EPS for the current year.

A hedge fund recently bought a new stake in Zafgen stock. Oxford Asset Management acquired a new stake in shares of Zafgen Inc. (NASDAQ:ZFGN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 236,362 shares of the biopharmaceutical company’s stock, valued at approximately $1,497,000. Oxford Asset Management owned about 0.87% of Zafgen as of its most recent SEC filing.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity, and severe obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.